TriSalus Life Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $10.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason McCarthy has given his Buy rating due to a combination of factors tied to the strength and versatility of TriSalus’s PEDD platform. He views the newly highlighted nelitolimod data as compelling evidence that Pressure Enabled Drug Delivery, via the TriNav system, can markedly improve intratumoral drug penetration, enhance immune activation, and reduce toxicity versus conventional catheter or systemic administration.
He further emphasizes that the value driver is the platform’s ability to extend beyond chemo and radiation into multiple therapeutic classes, including bispecifics, ADCs, checkpoints, cytokines, CAR-T, and potentially gene therapies. In his assessment, the combination of accelerating TriNav-based revenue in chemo/radiation, proof-of-concept in difficult-to-treat liver and pancreatic tumors, and growing partnering potential supports an attractive risk‑reward profile, justifying a Buy recommendation.
Jason McCarthy has given his Buy rating due to a combination of factors tied to the strength and versatility of TriSalus’s PEDD platform. He views the newly highlighted nelitolimod data as compelling evidence that Pressure Enabled Drug Delivery, via the TriNav system, can markedly improve intratumoral drug penetration, enhance immune activation, and reduce toxicity versus conventional catheter or systemic administration.
He further emphasizes that the value driver is the platform’s ability to extend beyond chemo and radiation into multiple therapeutic classes, including bispecifics, ADCs, checkpoints, cytokines, CAR-T, and potentially gene therapies. In his assessment, the combination of accelerating TriNav-based revenue in chemo/radiation, proof-of-concept in difficult-to-treat liver and pancreatic tumors, and growing partnering potential supports an attractive risk‑reward profile, justifying a Buy recommendation.
In another report released on March 6, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.
TLSI’s price has also changed moderately for the past six months – from $4.920 to $3.850, which is a -21.75% drop .